These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

160 related articles for article (PubMed ID: 22201865)

  • 1. Gliomagenesis: a game played by few players or a team effort?
    Mazzoleni S; Galli R
    Front Biosci (Elite Ed); 2012 Jan; 4(1):205-13. PubMed ID: 22201865
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Sox2, a stemness gene, regulates tumor-initiating and drug-resistant properties in CD133-positive glioblastoma stem cells.
    Song WS; Yang YP; Huang CS; Lu KH; Liu WH; Wu WW; Lee YY; Lo WL; Lee SD; Chen YW; Huang PI; Chen MT
    J Chin Med Assoc; 2016 Oct; 79(10):538-45. PubMed ID: 27530866
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Advances in histone deacetylase inhibitors in targeting glioblastoma stem cells.
    Reddy RG; Bhat UA; Chakravarty S; Kumar A
    Cancer Chemother Pharmacol; 2020 Aug; 86(2):165-179. PubMed ID: 32638092
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effective treatment of glioblastoma requires crossing the blood-brain barrier and targeting tumors including cancer stem cells: The promise of nanomedicine.
    Kim SS; Harford JB; Pirollo KF; Chang EH
    Biochem Biophys Res Commun; 2015 Dec; 468(3):485-9. PubMed ID: 26116770
    [TBL] [Abstract][Full Text] [Related]  

  • 5. In vitro demonstration of salinomycin as a novel chemotherapeutic agent for the treatment of SOX2‑positive glioblastoma cancer stem cells.
    Magrath JW; Raney WR; Kim Y
    Oncol Rep; 2020 Aug; 44(2):777-785. PubMed ID: 32627023
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Glioblastoma cancer stem-like cells: implications for pathogenesis and treatment.
    Nduom EK; Hadjipanayis CG; Van Meir EG
    Cancer J; 2012; 18(1):100-6. PubMed ID: 22290263
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Epidermal growth factor receptor expression identifies functionally and molecularly distinct tumor-initiating cells in human glioblastoma multiforme and is required for gliomagenesis.
    Mazzoleni S; Politi LS; Pala M; Cominelli M; Franzin A; Sergi Sergi L; Falini A; De Palma M; Bulfone A; Poliani PL; Galli R
    Cancer Res; 2010 Oct; 70(19):7500-13. PubMed ID: 20858720
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Proteins of the Wnt signaling pathway as targets for the regulation of CD133+ cancer stem cells in glioblastoma.
    Shevchenko V; Arnotskaya N; Korneyko M; Zaytsev S; Khotimchenko Y; Sharma H; Bryukhovetskiy I
    Oncol Rep; 2019 May; 41(5):3080-3088. PubMed ID: 30864699
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Temozolomide-induced increase of tumorigenicity can be diminished by targeting of mitochondria in in vitro models of patient individual glioblastoma.
    William D; Walther M; Schneider B; Linnebacher M; Classen CF
    PLoS One; 2018; 13(1):e0191511. PubMed ID: 29352318
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A molecular screening approach to identify and characterize inhibitors of glioblastoma stem cells.
    Visnyei K; Onodera H; Damoiseaux R; Saigusa K; Petrosyan S; De Vries D; Ferrari D; Saxe J; Panosyan EH; Masterman-Smith M; Mottahedeh J; Bradley KA; Huang J; Sabatti C; Nakano I; Kornblum HI
    Mol Cancer Ther; 2011 Oct; 10(10):1818-28. PubMed ID: 21859839
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Personalized regulation of glioblastoma cancer stem cells based on biomedical technologies: From theory to experiment (Review).
    Bryukhovetskiy I; Ponomarenko A; Lyakhova I; Zaitsev S; Zayats Y; Korneyko M; Eliseikina M; Mischenko P; Shevchenko V; Shanker Sharma H; Sharma A; Khotimchenko Y
    Int J Mol Med; 2018 Aug; 42(2):691-702. PubMed ID: 29749540
    [TBL] [Abstract][Full Text] [Related]  

  • 12. High density is a property of slow-cycling and treatment-resistant human glioblastoma cells.
    Sabelström H; Quigley DA; Fenster T; Foster DJ; Fuchshuber CAM; Saxena S; Yuan E; Li N; Paterno F; Phillips JJ; James CD; Norling B; Berger MS; Persson AI
    Exp Cell Res; 2019 May; 378(1):76-86. PubMed ID: 30844389
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Brain tumor stem cells as research and treatment targets.
    Hide T; Takezaki T; Nakamura H; Kuratsu J; Kondo T
    Brain Tumor Pathol; 2008; 25(2):67-72. PubMed ID: 18987831
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The role of octamer binding transcription factors in glioblastoma multiforme.
    Rooj AK; Bronisz A; Godlewski J
    Biochim Biophys Acta; 2016 Jun; 1859(6):805-11. PubMed ID: 26968235
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Heterogeneity of cancer-initiating cells within glioblastoma.
    Binda E; Visioli A; Reynolds B; Vescovi AL
    Front Biosci (Schol Ed); 2012 Jun; 4(4):1235-48. PubMed ID: 22652868
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Targeting cancer stem cells for treatment of glioblastoma multiforme.
    Cho DY; Lin SZ; Yang WK; Lee HC; Hsu DM; Lin HL; Chen CC; Liu CL; Lee WY; Ho LH
    Cell Transplant; 2013; 22(4):731-9. PubMed ID: 23594862
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Targeted nanocomplex carrying siRNA against MALAT1 sensitizes glioblastoma to temozolomide.
    Kim SS; Harford JB; Moghe M; Rait A; Pirollo KF; Chang EH
    Nucleic Acids Res; 2018 Feb; 46(3):1424-1440. PubMed ID: 29202181
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Resveratrol targeting of AKT and p53 in glioblastoma and glioblastoma stem-like cells to suppress growth and infiltration.
    Clark PA; Bhattacharya S; Elmayan A; Darjatmoko SR; Thuro BA; Yan MB; van Ginkel PR; Polans AS; Kuo JS
    J Neurosurg; 2017 May; 126(5):1448-1460. PubMed ID: 27419830
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Proneural-mesenchymal transformation of glioma stem cells: do therapies cause evolution of target in glioblastoma?
    Nakano I
    Future Oncol; 2014; 10(9):1527-30. PubMed ID: 25145421
    [No Abstract]   [Full Text] [Related]  

  • 20. Machine learning revealed stemness features and a novel stemness-based classification with appealing implications in discriminating the prognosis, immunotherapy and temozolomide responses of 906 glioblastoma patients.
    Wang Z; Wang Y; Yang T; Xing H; Wang Y; Gao L; Guo X; Xing B; Wang Y; Ma W
    Brief Bioinform; 2021 Sep; 22(5):. PubMed ID: 33839757
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.